查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012628

前列腺癌治療市場：依作用機制、治療線、劑型、通路和最終用戶分類－2026-2032年全球市場預測

Prostate Cancer Therapeutics Market by Therapeutic Mechanism, Therapy Line, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，攝護腺癌治療市場價值將達到 112.1 億美元，到 2026 年將成長至 118.4 億美元，到 2032 年將達到 175.9 億美元，複合年成長率為 6.64%。

主要市場統計數據
基準年 2025 112.1億美元
預計年份：2026年 118.4億美元
預測年份 2032 175.9億美元
複合年成長率 (%) 6.64%

未來，不斷發展的臨床實踐、診斷整合和治療方法創新將重新定義全球前列腺癌的治療和管理。

前列腺癌的治療正在經歷重大變革時期，這主要得益於分子診斷技術的進步、新型治療方法的湧現以及醫療服務模式的持續演進。近年來，臨床醫生和研發人員已從廣譜細胞毒性療法轉向精準醫療策略，後者能夠選擇性地靶向腫瘤的生物學特徵，並利用基因組分析和影像學技術識別出的弱點。同時，放射性藥物和標靶治療的創新正在重塑臨床對疾病控制和耐受性的預期，促使臨床醫生重新評估疾病各階段的治療順序和聯合策略。

診斷技術的突破、放射性藥物的引入、標靶治療和新的商業模式正在全面重塑前列腺癌的治療方案和治療途徑。

前列腺癌的治療格局正在經歷一場變革，這主要得益於診斷準確性的提高、新型治療方法的出現以及策略性商業化策略的融合。 PSMA標靶成像和擴展基因組檢測等診斷技術的進步，為臨床醫生提供了可操作的數據，有助於選擇標靶治療，從而能夠更早、更準確地識別PARP抑制劑和放射性配體療法的候選患者。同時，放射性藥物正從小眾臨床實驗走向針對特定患者族群的成熟治療方案，改變了臨床路徑和供應鏈的需求。

到 2025 年，進口藥品原料和特種放射性藥品的關稅政策變化對營運、供應鏈和取得的影響。

影響關稅和跨境貿易的政策變化會對依賴特殊原料和物流的治療藥物產生集中的下游影響。提高進口活性藥物成分、前驅化學品或放射性化學材料的關稅可能會增加製造商和合約研發生產機構（CDMO）的生產成本，進而影響定價策略、庫存緩衝和供應合約。鑑於放射性藥物生產和分銷的技術複雜性和監管限制，即使關稅體系的微小變化也會使採購決策複雜化，並需要短期營運調整。

每個細分市場的獨特影響，如治療機制、治療線、配方、分銷管道和終端用戶趨勢，塑造了臨床價值提案和產業計畫。

對細分市場的詳細分析闡明了臨床機會與商業性複雜性之間的交集。根據治療機制，該領域涵蓋化療、荷爾蒙療法、免疫療法、放射性藥物和標靶治療。化療類別進一步細分含鉑類藥物和紫杉烷類藥物。荷爾蒙療法類別細分為抗雄性激素、CYP17抑制劑、GnRH促效劑和GnRH拮抗劑。荷爾蒙療法透過癌症疫苗、細胞療法和查核點抑制劑進行考察。放射性藥物根據其α射線發射和BETA射線發射進行分析。標靶治療包括單株抗體、PARP抑制劑和蛋白酪氨酸激酶抑制劑。根據治療線數，治療途徑分為一線、二線、三線和後續治療。依劑型，給藥途徑分為注射劑和口服劑。根據分銷管道，管道包括醫院藥房、線上藥房和零售藥房。根據最終用戶，分析將涵蓋癌症中心、居家醫療提供者、醫院和專科診所。

對美洲、歐洲、中東和非洲以及亞太地區在實施狀況、基礎設施發展和報銷制度方面的差異進行比較分析，這些差異決定了獲得治療的趨勢。

區域趨勢顯著影響前列腺癌治療方案的引入、報銷和研發的優先順序。在美洲，臨床創新和商業化能力高度集中，這得益於完善的監管體系和先進診斷技術的廣泛應用。這種環境促進了放射性配體療法和生物標記主導的標靶治療的快速商業化，同時也促使支付方更加嚴格地審查，要求提供可靠的真實世界數據以支持永續的治療。相較之下，歐洲、中東和非洲地區在定價政策、報銷週期和醫療基礎設施方面存在差異。一些歐洲市場正在國家醫療體系下快速引入新的診斷方法和高成本治療方法，而其他市場則進展較為緩慢。此外，中東和非洲國家正在選擇性地投資核醫和腫瘤專科中心，作為其更廣泛的醫療體系強化工作的一部分。

深入了解決定公司在前列腺癌治療領域競爭地位和商業化準備的策略重點、合作框架和產能投資。

前列腺癌治療領域的企業策略體現了對標靶治療、策略聯盟和真實世界數據（REW）的大量投資。大型製藥企業正集中資源推進PARP抑制劑、新一代雄性激素受體拮抗劑和已通過核准藥物的生命週期管理，同時與核子醫學專家和契約製造合作，實現放射性配體療法的商業化。規模較小的生物技術和專業公司則專注於細胞療法和治療性疫苗等細分領域，著重於生物標記豐富的適應症，以加速臨床開發並實現差異化。

為商業、臨床和供應鏈領導者提供切實可行的、基於證據的策略，以加速藥物的採用、確保藥物的可及性，並降低藥物開發中政策主導的風險。

產業領導者應優先考慮將科學差異化與營運準備相結合的協作策略。首先，將診斷方法匯入流程整合到臨床開發專案中，並在產品上市前建立伴隨檢測和病患篩選系統。儘早與診斷服務提供者和保險公司合作，將有助於簡化產品導入和報銷方面的討論。其次，透過供應商多元化、關鍵原料的多年期合約以及拓展區域製造夥伴關係，增強供應鏈韌性，降低關稅和物流風險。第三，投資於產生超越大型臨床試驗的證據，包括註冊研究和可操作性研究，以捕捉真實世界的療效、安全性和衛生經濟學結果，從而支持報銷並增強處方醫生的信心。

透過整合二手證據、臨床試驗和監管審查、專家訪談和情境檢驗等嚴謹的多方面研究途徑，得出了可操作的見解。

本研究途徑結合了系統性的二手資料研究、與專家的直接交流以及多方面的數據匹配，旨在建立治療、監管和商業性趨勢的全面觀點。二手資料研究利用同儕審查文獻、臨床試驗註冊庫、監管公告和公開的公司文件，以了解治療機制、近期核准情況和研發管線活動。一手資料研究則包括對腫瘤學和核子醫學領域的關鍵意見領袖、供應鏈專家、支付方和臨床實踐專業人員進行結構化訪談，以檢驗趨勢、支持臨床決策模式並識別與專科產品分銷和管理相關的運營挑戰。

我們從策略上整合臨床創新、營運挑戰和協作重點，為永續獲取醫療資源和改善患者預後提供路線圖。

前列腺癌治療領域的不斷演變既帶來了巨大的機遇，也帶來了營運上的複雜性。標靶治療、放射性藥物和精準診斷技術的進步正推動臨床治療模式轉向更個人化的策略轉變，而分銷、生產和報銷體係也必須做出相應調整，以適應需要特殊處理且具有長期療效證據的治療方法。那些能夠將科學創新與切實可行的營運計劃相結合的機構——例如，加強供應鏈韌性、在診斷和分銷領域建立夥伴關係以及投資於真實世界療效研究——將更有能力將突破性成果轉化為永續的患者用藥途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：前列腺癌治療市場：依治療機制分類

  • 化療
    • 含鉑類藥物
    • 紫杉烷類藥物
  • 荷爾蒙療法
    • 抗雄激素
    • CYP17抑制劑
    • GnRH促效劑
    • GnRH拮抗劑
  • 免疫療法
    • 癌症疫苗
    • 細胞療法
    • 查核點抑制劑
  • 放射性藥物
    • α粒子發射材料
    • BETA射線放射體
  • 標靶治療
    • 單株抗體
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章：攝護腺癌治療市場：依治療線分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第10章 攝護腺癌治療市場：依劑型分類

  • 注射藥物
  • 口服

第11章 攝護腺癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 前列腺癌治療藥物市場：依最終用戶分類

  • 癌症中心
  • 居家醫療服務提供者
  • 醫院
  • 專科診所

第13章 攝護腺癌治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 前列腺癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 前列腺癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：攝護腺癌治療市場

第17章 中國：攝護腺癌治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA3266BF

The Prostate Cancer Therapeutics Market was valued at USD 11.21 billion in 2025 and is projected to grow to USD 11.84 billion in 2026, with a CAGR of 6.64%, reaching USD 17.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.21 billion
Estimated Year [2026] USD 11.84 billion
Forecast Year [2032] USD 17.59 billion
CAGR (%) 6.64%

A forward-looking overview of evolving clinical practice, diagnostic integration, and therapeutic innovation that are redefining how prostate cancer is treated and managed globally

Prostate cancer therapeutics are undergoing a period of meaningful transformation driven by advances in molecular diagnostics, novel therapeutic modalities, and evolving care delivery models. Over the last several years, clinicians and developers have shifted from broad cytotoxic approaches toward precision strategies that selectively target tumor biology and exploit vulnerabilities identified through genomic and imaging technologies. In parallel, innovations in radiopharmaceuticals and targeted therapies are reshaping clinical expectations for disease control and tolerability, prompting clinicians to rethink sequencing and combination strategies for different stages of disease.

This dynamic environment has created new opportunities and operational challenges for pharmaceutical developers, payers, providers, and patient support organizations. Stakeholders increasingly prioritize integration of diagnostic testing early in the care pathway to guide personalized regimens. Meanwhile, clinical trial design is adapting to include biomarker-enrichment, adaptive frameworks, and decentralized elements to accelerate enrollment and broaden patient representation. These shifts underscore the growing importance of multi-disciplinary collaboration among oncologists, nuclear medicine specialists, genetic counselors, and health systems to translate innovation into sustainable standards of care.

How diagnostic breakthroughs, radiopharmaceutical adoption, targeted agents, and new commercial models are collectively reshaping prostate cancer treatment protocols and access

The prostate cancer therapeutic landscape is experiencing transformative shifts driven by convergence of diagnostic precision, novel modalities, and strategic commercialization approaches. Diagnostic advances such as PSMA-targeted imaging and expanded genomic panels now provide clinicians with actionable data that inform targeted therapy selection, enabling earlier and more accurate identification of candidates for PARP inhibitors and radioligand therapies. Concurrently, radiopharmaceuticals have moved from niche investigational status to established therapeutic options for selected patient populations, altering both clinical pathways and supply chain requirements.

Innovation in targeted agents continues apace with incremental improvements in androgen receptor pathway inhibitors and next-generation small molecules that address resistance mechanisms. Immunotherapy efforts are refining patient selection to improve the modest response rates observed to date, while cell-based approaches and therapeutic vaccines persist as active research avenues. Commercial models are adapting to these scientific changes: manufacturers and providers are collaborating on specialized distribution, cold-chain logistics, and patient support programs to ensure timely access for therapies that require unique handling. These cumulative changes are propelling health systems to revise treatment algorithms and reimbursement strategies to accommodate higher-cost, higher-value interventions.

Operational, supply chain, and access implications of tariff policy changes on imported pharmaceutical inputs and specialized radiopharmaceutical materials through 2025

Policy shifts affecting tariffs and cross-border trade can have concentrated downstream effects on therapeutics that rely on specialized inputs and logistics. Increased tariffs on imported active pharmaceutical ingredients, precursor chemicals, or radiochemistry materials can raise production costs for manufacturers and contract development and manufacturing organizations, which in turn may influence pricing strategy, inventory buffers, and supply agreements. Given the technical complexity and regulatory constraints surrounding radiopharmaceutical production and distribution, even modest changes in tariff regimes can complicate sourcing decisions and necessitate near-term operational adjustments.

In response to tariff-driven cost pressures, stakeholders are already evaluating strategies to mitigate exposure. These measures include diversifying supplier portfolios, renegotiating long-term procurement contracts, accelerating nearshoring or regional manufacturing partnerships, and increasing investment in domestic capacity for radioligand synthesis. Additionally, health systems and payers may intensify scrutiny of comparative effectiveness and real-world outcomes to justify reimbursement for higher-cost therapies. Clinically, manufacturers must collaborate more closely with logistics providers to ensure predictable supply for time-sensitive therapies, and sponsors may need to build larger safety stocks for investigational agents used in multicenter trials. Collectively, these operational and strategic shifts will determine how tariff changes influence access, affordability, and the pace at which new therapies reach patients.

Segment-specific implications across therapeutic mechanism, therapy line, formulation, distribution channel, and end-user dynamics that shape clinical value propositions and operational planning

A granular view of segmentation clarifies where clinical opportunity and commercial complexity intersect. Based on therapeutic mechanism, the landscape spans Chemotherapy, Hormone Therapy, Immunotherapy, Radiopharmaceuticals, and Targeted Therapy; the Chemotherapy category further includes Platinum Compounds and Taxanes; the Hormone Therapy category is subdivided into Antiandrogens, CYP17 Inhibitors, GnRH Agonists, and GnRH Antagonists; Immunotherapy is examined through Cancer Vaccines, Cell Therapy, and Checkpoint Inhibitors; Radiopharmaceuticals are analyzed as Alpha Emitters and Beta Emitters; and Targeted Therapy encompasses Monoclonal Antibodies, Parp Inhibitors, and Tyrosine Kinase Inhibitors. Based on therapy line, therapeutic pathways are differentiated into First Line, Second Line, and Third Line and Beyond. Based on formulation, modalities are classified as Injectable and Oral. Based on distribution channel, channels include Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Based on end user, the analysis considers Cancer Centers, Homecare Providers, Hospitals, and Specialty Clinics.

From a strategic standpoint, therapeutic mechanism segmentation highlights where R&D investment yields the greatest differentiation; radiopharmaceuticals and targeted agents currently offer the strongest pathway to personalized outcomes, while cytotoxic chemotherapy continues to play a role in specific clinical scenarios. Therapy line segmentation informs value proposition and evidence generation needs, with later-line approvals frequently relying on biomarker-defined populations. Formulation segmentation drives commercial planning, since oral agents prioritize adherence initiatives and patient support infrastructure, whereas injectable or radiolabeled products necessitate specialized administration sites and cold-chain logistics. Distribution channel and end-user segmentation underscore the operational necessity of aligning distribution strategies with site capabilities, reimbursement environments, and patient preferences to maximize timely access and optimize care pathways.

Comparative analysis of regional adoption, infrastructure readiness, and reimbursement nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine therapeutic access trajectories

Regional dynamics materially influence adoption, reimbursement, and development priorities for prostate cancer therapeutics. In the Americas, clinical innovation and commercial launch capacity remain highly concentrated, supported by well-established regulatory pathways and broad adoption of advanced diagnostics; this environment incentivizes rapid commercialization of radioligand therapies and biomarker-driven targeted agents, while also generating payer scrutiny that requires robust real-world evidence to support durable access. In contrast, Europe, Middle East & Africa exhibits heterogeneity in pricing policies, reimbursement timelines, and healthcare infrastructure; some European markets adopt new diagnostics and high-cost therapies rapidly under national health systems while others progress incrementally, and countries across the Middle East and Africa are selectively investing in nuclear medicine and specialty oncology centers as part of broader health system strengthening efforts.

Asia-Pacific represents a mix of rapid clinical trial activity, expanding manufacturing capacity, and variable reimbursement maturity. Several countries in the region are emerging as important clinical development hubs, offering large patient populations for biomarker-driven studies and growing nuclear medicine capabilities to support radiopharmaceutical programmes. However, access remains uneven, with pricing pressure and local guideline adaptation influencing uptake. Across all regions, cross-border collaboration on clinical trials, harmonization of diagnostic standards, and investment in logistics for time-sensitive therapies are common strategic priorities that will determine the pace of adoption and the patient populations that will benefit most in the near term.

Insights into corporate strategic priorities, partnership frameworks, and capability investments that determine competitive positioning and commercialization readiness in prostate cancer therapeutics

Corporate strategies in prostate cancer therapeutics reflect deep investments in targeted modalities, strategic partnerships, and real-world evidence generation. Established pharmaceutical firms have concentrated resources on advancing PARP inhibitors, next-generation androgen receptor antagonists, and lifecycle management of approved assets, while also entering collaborations with nuclear medicine specialists and contract manufacturers to commercialize radioligand therapies. Smaller biotech and specialty companies are advancing niche approaches such as cell therapies and therapeutic vaccines, focusing on biomarker-enriched indications to expedite clinical development and maximize differentiation.

Across the competitive landscape, companies that demonstrate integrated capabilities-combining diagnostic partnerships, distribution networks for injectable and radiopharmaceutical products, and robust patient support programs-achieve a clear advantage in commercialization readiness. Strategic M&A and licensing deals continue to realign portfolios, enabling larger players to internalize specialized technologies and enabling mid-sized companies to leverage partners' commercialization channels. Additionally, firms investing in digital engagement tools, decentralized trial operations, and long-term real-world outcomes research position themselves to respond to payer demands and clinician preferences more rapidly. Collectively, these corporate actions are accelerating the translation of novel science into accessible treatment options while reshaping partner ecosystems.

Practical, evidence-focused strategies for commercial, clinical, and supply chain leaders to accelerate adoption, protect access, and mitigate policy-driven risks in therapeutic development

Industry leaders should prioritize coordinated strategies that align scientific differentiation with operational readiness. First, integrate diagnostic adoption pathways into clinical development programs to ensure companion tests and patient identification capabilities are established ahead of launch; early collaboration with diagnostic providers and payers will streamline uptake and reimbursement discussions. Second, strengthen supply chain resiliency by diversifying suppliers, negotiating multi-year agreements for critical inputs, and expanding regional manufacturing partnerships to mitigate tariff and logistics risks. Third, invest in evidence generation that extends beyond pivotal trials to include registries and pragmatic studies capturing real-world effectiveness, safety, and health economic outcomes to support reimbursement and prescriber confidence.

Beyond these core actions, organizations should re-evaluate distribution strategies to accommodate the growing role of homecare and specialty clinics for injectable and radiopharmaceutical products, while designing patient support programs that improve adherence for oral agents and facilitate timely access for complex therapies. Firms must also cultivate cross-disciplinary KOL engagement and payer dialogues to co-develop value frameworks that reflect long-term clinical benefit. Lastly, embrace flexible commercial models including risk-sharing arrangements and outcomes-based contracting where appropriate, and maintain scenario planning capabilities to respond rapidly to policy shifts, tariff adjustments, and evolving clinical guidelines.

A rigorous multi-method research approach integrating secondary evidence, clinical trial and regulatory review, expert interviews, and scenario validation to produce actionable insights

The research approach combined systematic secondary research, primary expert engagement, and multi-source data triangulation to assemble a comprehensive perspective on therapeutic, regulatory, and commercial dynamics. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory announcements, and company publications to map therapeutic mechanisms, recent approvals, and pipeline activity. Primary research consisted of structured interviews with key opinion leaders in oncology, nuclear medicine, supply chain professionals, payers, and clinical operations experts to validate trends, corroborate clinical decision-making patterns, and surface operational challenges tied to distribution and administration of specialized products.

Analytical rigor was reinforced through cross-validation of findings across multiple data inputs and scenario analysis to test susceptibility to policy and supply disruptions. The methodology emphasized qualitative synthesis and contextual interpretation of clinical trial evidence and regulatory trajectories rather than quantitative projections, and it incorporated stakeholder workshops to ensure the final recommendations align with practical operational constraints and strategic imperatives. This layered approach supports robust, actionable insight for decision-makers across commercial, clinical development, and supply chain functions.

A strategic synthesis of clinical innovation, operational imperatives, and collaborative priorities that frames the pathway to sustainable access and improved patient outcomes

The evolving prostate cancer therapeutics landscape presents both profound opportunity and operational complexity. Advances in targeted agents, radiopharmaceuticals, and diagnostic precision are shifting clinical paradigms toward more personalized strategies, while distribution, manufacturing, and reimbursement systems must adapt to accommodate therapies that require specialized handling and evidence to demonstrate long-term value. Organizations that align scientific innovation with pragmatic operational planning-strengthening supply resilience, forging diagnostic and distribution partnerships, and investing in real-world outcomes research-will be best positioned to translate breakthroughs into sustainable patient access.

Looking ahead, collaboration across industry, clinical, and policy stakeholders will be essential to reconcile rapid therapeutic innovation with equitable access and cost-effectiveness. By anticipating shifts in payer expectations, regulatory requirements, and regional infrastructure constraints, stakeholders can proactively design development and commercialization programs that deliver clinical benefit while safeguarding operational viability. The strategic choices made today will determine which therapies reach patients efficiently and which approaches set the standard for next-generation prostate cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism

  • 8.1. Chemotherapy
    • 8.1.1. Platinum Compounds
    • 8.1.2. Taxanes
  • 8.2. Hormone Therapy
    • 8.2.1. Antiandrogens
    • 8.2.2. CYP17 Inhibitors
    • 8.2.3. GnRH Agonists
    • 8.2.4. GnRH Antagonists
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Cell Therapy
    • 8.3.3. Checkpoint Inhibitors
  • 8.4. Radiopharmaceuticals
    • 8.4.1. Alpha Emitters
    • 8.4.2. Beta Emitters
  • 8.5. Targeted Therapy
    • 8.5.1. Monoclonal Antibodies
    • 8.5.2. Parp Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Prostate Cancer Therapeutics Market, by Therapy Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line And Beyond

10. Prostate Cancer Therapeutics Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral

11. Prostate Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Prostate Cancer Therapeutics Market, by End User

  • 12.1. Cancer Centers
  • 12.2. Homecare Providers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Prostate Cancer Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Prostate Cancer Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Prostate Cancer Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Prostate Cancer Therapeutics Market

17. China Prostate Cancer Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Astellas Pharma Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Celgene Corporation
  • 18.12. Eisai Inc.
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Genentech, Inc.
  • 18.16. GlaxoSmithKline plc
  • 18.17. Ipsen S.A.
  • 18.18. Janssen Pharmaceuticals, Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Novartis AG
  • 18.21. Pfizer Inc.
  • 18.22. Sanofi S.A.
  • 18.23. Takeda Pharmaceutical Company Limited
  • 18.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)